(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum. (3) 2009 addendum. - NGC

National Institute for Health and Clinical Excellence (NICE)
(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum. (3) 2009 addendum. This is an addendum to a previously published guideline summary.

GUIDELINE TITLE
(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum. (3) 2009 addendum.

BIBLIOGRAPHIC SOURCE(S)
National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Aug 01. 84 p. (Technology appraisal guidance; no. 111).

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previously published: National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Sep. 62 p. (Technology appraisal guidance; no. 111).


abrir aquí:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15322&nbr=&string=